Antibacterial Effects of Moxifloxacin and Levofloxacin Simulating Epithelial Lining Fluid Concentrations gainst Community-Acquired Methicillin-Resistant
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background and objective: Current North American guidelines advocate the use of respiratory fluoroquinolones for the empirical management of community-acquired pneumonia (CAP). While community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as a pathogen frequently encountered in skin and skin structure infections, it has also now been recognised as a causative pathogen in CAP. Since fluoroquinolones may be used empirically to treat unsuspected CA-MRSA pneumonia, the objective of this study was to evaluate the antibacterial properties of levofloxacin and moxifloxacin using human simulated drug exposures in epithelial lining fluid (ELF).
Methods: An in vitro model was used to simulate the ELF concentrations, previously determined in older adults receiving multiple doses, of levofloxacin 500mg once daily and moxifloxacin 400mg once daily. Four CA-MRSA isolates were studied at a starting inoculum of 106 colony-forming units (CFU)/mL; selected isolates were also studied at 108 CFU/mL. Bacterial density and resistance were quantitatively assessed over 48 hours. Drug exposure (area under the concentration-time curve [AUC]) was confirmed using validated drug assays.
Results: At a standard 106 starting inoculum, sustained bacterial kill (3.6–4.5 log) with both fluoroquinolones was noted for CA-MRSA isolates 27 and 44 (AUC/minimum inhibitory concentration [MIC] = 383–3923). Despite an MIC of 8 μg/ mL (AUC/MIC = 25) for isolate 3, levofloxacin displayed a 2.8 log kill, while moxifloxacin (MIC 1 μg/mL) sustained a 4.5 log kill (AUC/MIC = 207) over 48 hours. Against isolate 59, levofloxacin displayed no antibacterial effect (AUC/MIC = 3), while moxifloxacin with an MIC of 8 μg/mL (AUC/MIC = 31) killed 4.6 log. At a high inoculum (108), both fluoroquinolones showed 5.2–5.6 log kill for the susceptible isolate (44), while moxifloxacin showed no antibacterial activity against isolate 59. Drug exposure (AUC/MIC) appeared to correlate well (r2 = 0.99) with the change in log CFU/mL. Maximal activity was observed for both drugs at an AUC/MIC of approximately 30.
Conclusion: When evaluated at human simulated ELF concentrations, both levofloxacin and moxifloxacin appeared to demonstrate sustained antibacterial activity for CA-MRSA isolates with MICs ≤ 8 μg/mL at a starting inoculum of 106. Use of a high inoculum (108) appeared to compromise the antimicrobial activity of the fluoroquinolones when the MIC was 8 μg/mL, but did not mitigate antibacterial kill for susceptible isolates.
- Mandell, LA, Bartlett, JG, Dowell, SF (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37: pp. 1405-33 CrossRef
- Niederman, MS, Mandell, LA, Anzueto, A (2001) Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163: pp. 1730-54
- Naimi, TS, LeDell, KH, Como-Sabetti, K (2003) Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290: pp. 2976-84 CrossRef
- Lee, SY, Kuti, JL, Nicolau, DP (2005) Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 6: pp. 283-95 CrossRef
- Dufour, P, Gillet, Y, Bes, M (2002) Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 35: pp. 819-24 CrossRef
- Martinez-Aguilar, G, Hammerman, WA, Mason, EO (2003) Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 22: pp. 593-8
- Hageman, JC, Uyeki, TM, Francis, JS (2006) Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis 12: pp. 894-9 CrossRef
- Bradley, SF (2005) Staphylococcus aureus pneumonia: emergence of MRSA in the community. Semin Respir Crit Care Med 26: pp. 643-9 CrossRef
- Francis, JS, Doherty, MC, Lopatin, U (2005) Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40: pp. 100-7 CrossRef
- Abi-Hanna, P, Frank, AL, Quinn, JP (2000) Clonal features of community-acquired methicillin-resistant Staphylococcus aureus in children. Clin Infect Dis 30: pp. 630-1 CrossRef
- Frank, AL, Marcinak, JF, Mangat, PD (2002) Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 21: pp. 530-4 CrossRef
- Performance standards for antimicrobial susceptibility testing, 15th informational supplement M100–S16. Wayne (PA): Clinical Laboratory Standards Institute.
- Florea, NR, Tessier, PR, Zhang, C (2004) Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob Agents Chemother 48: pp. 1215-21 CrossRef
- Capitano, B, Mattoes, HM, Shore, E (2004) Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125: pp. 965-73 CrossRef
- Onyeji, CO, Bui, KQ, Owens, RC (1999) Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicemia. Int J Antimicrob Agents 12: pp. 107-14 CrossRef
- Firsov, AA, Vostrov, SN, Kononenko, OV (1999) Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother 43: pp. 498-502
- Yamagishi, J, Kojima, T, Oyamada, Y (1996) Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 40: pp. 1157-63
- Ferrero, L, Cameron, B, Crouzet, J (1995) Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 39: pp. 1554-8 CrossRef
- Horii, T, Suzuki, Y, Monji, A (2003) Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs. Diagn Microbiol Infect Dis 46: pp. 139-45 CrossRef
- Noguchi, N, Okihara, T, Namiki, Y (2005) Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Int J Antimicrob Agents 25: pp. 374-9 CrossRef
- Craig, WA, Andes, DR, Ambrose, PG (2005) In vivo pharmacodynamic activity of gatifloxacin, levofloxacin, and moxifloxacin against Staphylococcus aureus with reduced susceptibility to fluoroquinolones (abstract).
- Fridkin, SK, Hageman, JC, Morrison, M (2005) Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352: pp. 1436-44 CrossRef
- Neuhauser, MM, Weinstein, RA, Rydman, R (2003) Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289: pp. 885-8 CrossRef
- MacDougall, C, Powell, JP, Johnson, CK (2005) Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 41: pp. 435-40 CrossRef
- Charbonneau, P, Parienti, JJ, Thibon, P (2006) Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 42: pp. 778-84 CrossRef
- Firsov, AA, Vostrov, SN, Lubenko, IY (2004) Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Int J Antimicrob Agents 23: pp. 451-6 CrossRef
- Schrenzel, J, Harbarth, S, Schockmel, G (2004) A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis 39: pp. 1285-92 CrossRef
- Antibacterial Effects of Moxifloxacin and Levofloxacin Simulating Epithelial Lining Fluid Concentrations gainst Community-Acquired Methicillin-Resistant
Drugs in R & D
Volume 8, Issue 2 , pp 69-77
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, Connecticut, 06102, USA
- 2. Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA